bet inhibitors in the treatment of hematologic malignancies: current insights and future prospects
Clicks: 286
ID: 139001
2016
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
8.1
/100
27 views
27 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Sameem M Abedin,1 Craig S Boddy,1 Hidayatullah G Munshi1–3 1Department of Medicine, Feinberg School of Medicine, Northwestern University, 2Medicine Service, Jesse Brown VA Medical Center, 3The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA Abstract: The bromodomain and extra-terminal (BET) family of proteins are important epigenetic regulators involved in promoting gene expression of critical oncogenes. BET inhibitors have been demonstrated to repress c-Myc expression, and were initially shown to have efficacy in a number of c-Myc-dependent hematologic malignancies. Recent studies have now revealed a broader role for BET inhibitors in hematologic malignancies. In this review, we summarize the efficacy of BET inhibitors in preclinical models of acute leukemia, lymphoma, and multiple myeloma. We also summarize recent results of clinical trials utilizing BET inhibitors in hematologic malignancies, characterize potential resistance mechanisms to BET inhibitors, and discuss potential combination therapies with BET inhibitors in patients with hematologic malignancies. Keywords: leukemia, lymphoma, multiple myeloma, toxicity, resistance mechanisms
| Reference Key |
sm2016oncotargetsbet
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Abedin SM;Boddy CS;Munshi HG |
| Journal | jurnal tam |
| Year | 2016 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.